High Expression of a CD38-Like Molecule in Normal Prostatic Epithelium and its Differential Loss in Benign and Malignant Disease-Reference-Cited by-同舟云学术

High Expression of a CD38-Like Molecule in Normal Prostatic Epithelium and its Differential Loss in Benign and Malignant Disease

Published:1995-11 Issue:5 Volume:154 Page:1636-1641
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kramer G.¹,Steiner G.¹,Fodinger D.¹,Fiebiger E.¹,Rappersberger C.¹,Binder S.¹,Hofbauer J.¹,Marberger M.¹

Affiliation:

1. Departments of Urology, Dermatology and Pathology, University of Vienna, and Institute of Immunology, Vienna International Research Center, Vienna, Austria.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference22 articles.

1. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage;Reinherz;Proc. Natl. Acad. Sci.,1980

2. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation;Jackson;J. Immunol.,1990

3. Distribution of t lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies;Janossy;J. Immunol.,1981

4. Kinetics of activation antigen expression by in vitro-stimulated human T lymphocytes;Holter;Cell. Immunol.,1985

5. Stages of B cell differentiation in human lymphoid tissue;Bhan;J. Exp. Med.,1981

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD38 Deficiency Protects Mouse Retinal Ganglion Cells Through Activating the NAD+/Sirt1 Pathway in Ischemia-Reperfusion and Optic Nerve Crush Models;Investigative Ophthalmology & Visual Science;2024-05-22

2. Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis;Current Oncology;2022-12-22

3. CD38 a biomarker and therapeutic target in non-hematopoietic tumors;Biomarkers in Medicine;2022-04

4. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma;Frontiers in Immunology;2020-06-05

5. Prostate Luminal Progenitor Cells in Development and Cancer;Trends in Cancer;2018-11